OBJECTIVES: Sirtuin 3 (SIRT3) can protect cardiomyocytes from oxidative stress-mediated cell damage and prevent cardiac hypertrophy development. The aim of this study was to evaluate whether a relationship existed between left ventricular mass index (LVMI) and serum SIRT3 levels in patients with hypertension. PATIENTS AND METHODS: This study was conducted as a cross-sectional study of 83 patients between April 2018 and October 2018. The LVMI of all patients was calculated using the formula of the American Echocardiography Association and patients were divided into two groups according to results (increased LVMI and normal LVMI). RESULTS: Increased LVMI was determined in 37.3% of patients, whereas 62.7% had normal LVMI. There was no significant difference between serum SIRT3 levels between those with increased LVMI and normal LVMI (5.8 versus 5.4 ng/ml; P = 0.914). Serum pro-brain natriuretic peptide levels (69 versus 41 ng/ml; P = 0.019) were found to be higher in patients with increased LVMI than in those with normal LVMI. A positive correlation between SIRT3 levels and Sm (myocardial systolic) velocity was also determined (r = 0.338; P = 0.002). CONCLUSION: The serum levels of SIRT3, a molecule which has been proposed to have protective properties against myocardial hypertrophy, were not found to be correlated with LVMI values; however, SIRT3 levels were found to be correlated with Sm velocity, which is accepted to be an indicator of myocardial early diastolic dysfunction.
OBJECTIVES: Sirtuin 3 (SIRT3) can protect cardiomyocytes from oxidative stress-mediated cell damage and prevent cardiac hypertrophy development. The aim of this study was to evaluate whether a relationship existed between left ventricular mass index (LVMI) and serum SIRT3 levels in patients with hypertension. PATIENTS AND METHODS: This study was conducted as a cross-sectional study of 83 patients between April 2018 and October 2018. The LVMI of all patients was calculated using the formula of the American Echocardiography Association and patients were divided into two groups according to results (increased LVMI and normal LVMI). RESULTS: Increased LVMI was determined in 37.3% of patients, whereas 62.7% had normal LVMI. There was no significant difference between serum SIRT3 levels between those with increased LVMI and normal LVMI (5.8 versus 5.4 ng/ml; P = 0.914). Serum pro-brain natriuretic peptide levels (69 versus 41 ng/ml; P = 0.019) were found to be higher in patients with increased LVMI than in those with normal LVMI. A positive correlation between SIRT3 levels and Sm (myocardial systolic) velocity was also determined (r = 0.338; P = 0.002). CONCLUSION: The serum levels of SIRT3, a molecule which has been proposed to have protective properties against myocardial hypertrophy, were not found to be correlated with LVMI values; however, SIRT3 levels were found to be correlated with Sm velocity, which is accepted to be an indicator of myocardial early diastolic dysfunction.
Authors: Vinodkumar B Pillai; Nagalingam R Sundaresan; Valluvan Jeevanandam; Mahesh P Gupta Journal: Cardiovasc Res Date: 2010-08-04 Impact factor: 10.787
Authors: Anna E Dikalova; Alfiya T Bikineyeva; Klaudia Budzyn; Rafal R Nazarewicz; Louise McCann; William Lewis; David G Harrison; Sergey I Dikalov Journal: Circ Res Date: 2010-05-06 Impact factor: 17.367
Authors: Otto A Sanchez; David R Jacobs; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; Daniel A Duprez Journal: J Hypertens Date: 2015-05 Impact factor: 4.844
Authors: Michael H Olsen; Kristian Wachtell; Olav W Nielsen; Christian Hall; Ragnhild Wergeland; Hans Ibsen; Sverre E Kjeldsen; Richard B Devereux; Björn Dahlöf; Per R Hildebrandt Journal: J Hypertens Date: 2006-08 Impact factor: 4.844
Authors: Sergey I Dikalov; Rafal R Nazarewicz; Alfiya Bikineyeva; Lula Hilenski; Bernard Lassègue; Kathy K Griendling; David G Harrison; Anna E Dikalova Journal: Antioxid Redox Signal Date: 2013-10-30 Impact factor: 8.401
Authors: Alexander R Moschen; Verena Wieser; Romana R Gerner; Alexandra Bichler; Barbara Enrich; Patrizia Moser; Christoph F Ebenbichler; Susanne Kaser; Herbert Tilg Journal: J Hepatol Date: 2013-08-06 Impact factor: 25.083
Authors: Augusto C Montezano; Maria Dulak-Lis; Sofia Tsiropoulou; Adam Harvey; Ana M Briones; Rhian M Touyz Journal: Can J Cardiol Date: 2015-02-14 Impact factor: 5.223